Browse by author
Lookup NU author(s): Marcus BrookesORCiD, Dr Michael Parry, Dr Kenneth RankinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022 Wiley Periodicals LLC. Background: Ewing sarcoma (ES) is the second most common primary bone malignancy, with an urgent need for new treatments. ES is associated with high rates of progression and relapse, driven by drug-resistant cells capable of migration, self-renewal and single-cell tumorigenesis, termed cancer stem-like cells (CSCs). Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a membrane-bound proteolytic enzyme, which, via direct and indirect mechanisms, digests four of the main types of collagen. This can be hijacked in malignancy for invasion and metastasis, with high expression predicting decreased survival in multiple cancers. In this study, we have examined the hypothesis that MT1-MMP is expressed by ES cells and explored the relationship between expression and outcomes. Procedure: MT1-MMP expression in ES established cell lines, primary patient-derived cultures and daughter ES-CSCs was characterised by RNA sequencing, Western blotting, immunocytochemistry and flow cytometry. Immunohistochemistry was used to detect MT1-MMP in tumour biopsies, and the relationship between expression, event-free and overall survival examined. Results: MT1-MMP was detected at both RNA and protein levels in five of six established cell lines, all primary cultures (n = 25) and all daughter ES-CSCs (n = 7). Immunohistochemistry of treatment-naïve biopsy tissue demonstrated that high MT1-MMP expression predicted decreased event-free and overall survival (p =.017 and.036, respectively; n = 47); this was not significant in multivariate analysis. Conclusions: MT1-MMP is expressed by ES cells, including ES-CSCs, making it a candidate therapeutic target. The level of MT1-MMP expression at diagnosis may be considered as a prognostic biomarker if validated by retrospective analysis of a larger cohort of clinical trial samples.
Author(s): Brookes MJ, Roundhill EA, Jeys L, Parry M, Burchill SA, Rankin KS
Publication type: Article
Publication status: Published
Journal: Pediatric Blood and Cancer
Year: 2022
Volume: 69
Issue: 12
Print publication date: 01/12/2022
Online publication date: 15/09/2022
Acceptance date: 09/08/2022
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1002/pbc.29959
DOI: 10.1002/pbc.29959
Altmetrics provided by Altmetric
